CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 165 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,565,025 | +119.4% | 96,326 | +148.8% | 0.00% | 0.0% |
| Q1 2024 | $1,624,617 | +17.5% | 38,709 | +11.0% | 0.00% | 0.0% |
| Q4 2023 | $1,382,865 | +44.1% | 34,868 | 0.0% | 0.00% | – |
| Q3 2023 | $959,567 | -16.0% | 34,868 | +9.8% | 0.00% | -100.0% |
| Q2 2023 | $1,142,293 | 0.0% | 31,748 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,142,293 | -15.3% | 31,748 | +5.0% | 0.00% | 0.0% |
| Q4 2022 | $1,347,887 | -99.8% | 30,242 | 0.0% | 0.00% | – |
| Q3 2022 | $850,103,000 | +7.1% | 30,242 | +2.7% | 0.00% | – |
| Q2 2022 | $793,675,000 | -29.6% | 29,439 | -11.0% | 0.00% | – |
| Q1 2022 | $1,127,012,000 | -11.9% | 33,089 | 0.0% | 0.00% | – |
| Q4 2021 | $1,278,559,000 | -34.6% | 33,089 | -8.6% | 0.00% | -100.0% |
| Q3 2021 | $1,954,978,000 | +71.9% | 36,210 | +6.5% | 0.00% | – |
| Q2 2021 | $1,137,361,000 | +56.1% | 34,012 | -3.9% | 0.00% | – |
| Q1 2021 | $728,766,000 | +22.4% | 35,377 | +4.1% | 0.00% | – |
| Q4 2020 | $595,452,000 | – | 33,987 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |